These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 2119665)

  • 1. Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction.
    White HD; Cross DB; Williams BF; Norris RM
    Br Heart J; 1990 Sep; 64(3):177-81. PubMed ID: 2119665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of creatine kinase isoforms for diagnosis of infarct artery patency after thrombolytic therapy with streptokinase.
    Norris RM; Twigden DG; Williams BF; Johnson RN; White HD
    Coron Artery Dis; 1993 Feb; 4(2):201-5. PubMed ID: 8269212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy.
    Baardman T; Hermens WT; Lenderink T; Molhoek GP; Grollier G; Pfisterer M; Simoons ML
    Eur Heart J; 1996 Feb; 17(2):237-46. PubMed ID: 8732377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
    GUSTO Angiographic Investigators
    N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: incidence and effect of smoking.
    Rivers JT; White HD; Cross DB; Williams BF; Norris RM
    J Am Coll Cardiol; 1990 Aug; 16(2):340-8. PubMed ID: 2115538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers.
    Steg PG; Laperche T; Golmard JL; Juliard JM; Benamer H; Himbert D; Aubry P
    J Am Coll Cardiol; 1998 Mar; 31(4):776-9. PubMed ID: 9525545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative effect of streptokinase and alteplase on electrocardiogram and angiogram signs of myocardial reperfusion in ST segment elevation acute myocardial infarction].
    Tomasević M; Kostić T; Apostolović S; Perisić Z; Djordjević-Radojković D; Koraćević G; Salinger-Martinović S
    Srp Arh Celok Lek; 2008; 136(9-10):481-7. PubMed ID: 19069338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators.
    Goodman SG; Langer A; Ross AM; Wildermann NM; Barbagelata A; Sgarbossa EB; Wagner GS; Granger CB; Califf RM; Topol EJ; Simoons ML; Armstrong PW
    Circulation; 1998 Feb; 97(5):444-50. PubMed ID: 9490238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrocardiographic and enzymatic infarct size in a randomised study of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Hackworthy RA; Sorensen SG; Menlove RL; Anderson JL
    Drugs; 1987; 33 Suppl 3():198-208. PubMed ID: 3315592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Kentucky Acute Myocardial Infarction Trial (KAMIT) Group.
    Grines CL; Nissen SE; Booth DC; Gurley JC; Chelliah N; Wolf R; Blankenship J; Branco MC; Bennett K; DeMaria AN
    Circulation; 1991 Aug; 84(2):540-9. PubMed ID: 1907228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peak creatine kinase as a measure of effectiveness of thrombolytic therapy in acute myocardial infarction.
    Gore JM; Roberts R; Ball SP; Montero A; Goldberg RJ; Dalen JE
    Am J Cardiol; 1987 Jun; 59(15):1234-8. PubMed ID: 3109227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive diagnosis of arterial patency after thrombolytic treatment and its relation to prognosis.
    Norris RM; White HD; Cross DB; Woo KS; Elliott JM; Twigden D; Williams B; Johnson RN
    Br Heart J; 1993 Jun; 69(6):485-91. PubMed ID: 8343313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Langer A; Krucoff MW; Klootwijk P; Veldkamp R; Simoons ML; Granger C; Califf RM; Armstrong PW
    J Am Coll Cardiol; 1995 Jun; 25(7):1552-7. PubMed ID: 7759706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group.
    Zeymer U; Tebbe U; Essen Rv; Haarmann W; Neuhaus KL
    Am Heart J; 1999 Jan; 137(1):34-8. PubMed ID: 9878934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I thrombolysis in myocardial infarction (TIMI) trial. The TIMI Investigators.
    Habib GB; Heibig J; Forman SA; Brown BG; Roberts R; Terrin ML; Bolli R
    Circulation; 1991 Mar; 83(3):739-46. PubMed ID: 1900223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction.
    Magnani B
    J Am Coll Cardiol; 1989 Jan; 13(1):19-26. PubMed ID: 2491867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex (APSAC).
    Johnson ES; Cregeen RJ
    Drugs; 1987; 33 Suppl 3():298-311. PubMed ID: 3315612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies.
    Barbash GI; Birnbaum Y; Bogaerts K; Hudson M; Lesaffre E; Fu Y; Goodman S; Houbracken K; Munsters K; Granger CB; Pieper K; Califf RM; Topol EJ; Van De Werf F
    Circulation; 2001 Feb; 103(7):954-60. PubMed ID: 11181469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.